• Bioregenx posted a net loss of $26,415 for the quarter ended March 31, 2026, narrowing from the prior-year quarter on lower operating costs and higher other income.
• Net sales fell 17% to $426,175 versus the prior-year quarter, reflecting product issues with its medical testing machine that weighed on nutritional sales.
• Operating loss narrowed 74% to $49,764 as total operating expenses dropped 34% to $398,052, helped by a sharp reduction in selling, general and administrative spending.
• Other income was $100,435, driven by $81,334 of write-offs of accrued expenses and $19,101 of bad-debt recovery, while interest expense and financing costs rose 4% to $77,086.
• Cash on hand was $45,806 at March 31, 2026, with $522,500 of notes payable in default and management flagging substantial doubt about its ability to continue as a going concern.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioregenx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-004178), on May 20, 2026, and is solely responsible for the information contained therein.